maybe it's time...but i expect one more pushie push lower to load up
Rosetta Genomics seems like the best way to play the miRNA game with countless opportunities in the diagnostics field as well as in licensing deals. The company started exploring miRNAs years ahead of anyone else in the industry, using a unique approach that starts with computational modeling and ends with biological validation. As a result, Rosetta currently has the most prolific discovery platform in the industry that will enable it to maintain a constant flow of diagnostic products into the market. In addition, it possesses the most extensive patent portfolio that covers more than half of all known miRNAs, their roles and potential applications. Finally, Rosetta is the only miRNA pure-play, with the vast majority of its resources dedicated to diagnostics.
The rest of the companies are either not sufficiently focused on miRNAs or suffer from too much exposure to the therapeutic side. Investing in Alnylam or Isis just for the sake of miRNA seems premature, as Regulus is active only in the therapeutics market.